FREE PREMIUM SUBSCRIPTION FOR 14 DAYS!

ChemoCentryx Stock Forecast NASDAQ:CCXI

Price Target and Analyst Ratings

Most Recent Rating

Canaccord Genuity is very positive about CCXI and gave it a "Buy" rating on July 07, 2021. The price target was set to $79.00.

Last 30 Days

Over the last 30 days, this security got 2 buy, 0 sell, and 0 hold ratings.

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-07-07 Buy Reiterated by Canaccord Genuity $14.47 $79.00
2021-07-06 Hold - Buy Upgraded by Stifel Nicolaus $14.05
2021-05-13 Neutral - Underweight Reiterated by JPMorgan Chase & Co. $9.97 $57.00 → $17.00
2021-05-13 Strong-Buy - Outperform Reiterated by Raymond James $9.97 $120.00 → $51.00
2021-05-13 Outperform - Market Perform Reiterated by SVB Leerink $9.97 $84.00 → $17.00
2021-05-13 Buy - Hold Reiterated by Stifel Nicolaus $9.97 $93.00 → $26.00
2021-05-13 Buy Target Lowered by HC Wainwright $9.97 $101.00 → $28.00
2021-05-12 Overweight - Neutral Reiterated by Piper Sandler $10.05 $80.00 → $25.00
2021-05-07 Buy Target Lowered by HC Wainwright $10.46 $101.00 → $28.00
2021-05-07 Buy - Hold Downgraded by Stifel Nicolaus $10.46
2021-05-07 Neutral - Underweight Downgraded by JPMorgan Chase & Co. $10.46 $57.00 → $17.00
2021-05-07 Outperform - Market Perform Downgraded by SVB Leerink $10.46
2021-05-07 Strong-Buy - Outperform Downgraded by Raymond James $10.46 $120.00 → $51.00
2021-05-06 Overweight - Neutral Downgraded by Piper Sandler $27.49
2021-05-05 Buy Reiterated by Canaccord Genuity $27.49
2021-03-08 Strong-Buy Target Raised by Raymond James $55.29 $119.00 → $120.00
2021-03-08 Buy Initiated by Stifel Nicolaus $55.29 $93.00
2021-03-02 Strong-Buy Target Raised by Raymond James $66.80 $119.00 → $120.00
2021-03-02 Buy Target Raised by HC Wainwright $66.80 $83.00 → $101.00
2021-03-01 Buy Initiated by Stifel Nicolaus $68.40
2021-01-08 Strong-Buy Target Raised by Raymond James $62.78 $100.00 → $119.00
2020-10-29 Overweight Target Lowered by Wells Fargo & Company $49.52 $79.00 → $70.00
2020-10-29 Outperform Target Raised by SVB Leerink $49.52 $75.00 → $84.00
2020-10-29 Overweight Target Raised by Piper Sandler $49.52 $67.00 → $71.00
2020-10-29 Overweight - Neutral Downgraded by JPMorgan Chase & Co. $49.52 $63.00 → $60.00
2020-09-17 Target Raised by HC Wainwright $52.57 $73.00 → $85.00
2020-08-12 Outperform Target Raised by SVB Leerink $52.99 $65.00 → $75.00
2020-08-12 Outperform Target Raised by SVB Leerink $52.99 $65.00 → $75.00
2020-08-11 Strong-Buy Target Raised by Raymond James $53.66 $95.00 → $100.00
2020-07-29 Overweight Target Lowered by JPMorgan Chase & Co. $52.65 $64.00 → $61.00
2020-06-16 Buy Initiated by BTIG Research $62.16 $70.00
2020-06-03 Buy Reiterated by Canaccord Genuity $60.58
2020-05-27 Overweight Initiated by Wells Fargo & Co $63.14 $79.00
2020-05-19 Buy Target Lowered by Canaccord Genuity $56.02 $68.00 → $58.00
2020-05-18 Reduce - Overweight Target Raised by Piper Sandler $58.49 $54.00 → $70.00
2020-05-14 Overweight Target Raised by JPMorgan Chase & Co. $52.22 $61.00 → $64.00
2020-05-12 Buy Target Raised by Canaccord Genuity $56.52 $64.00 → $68.00
2020-05-12 Outperform Target Raised by SVB Leerink $56.52 $54.00 → $65.00
2020-05-12 Strong-Buy Target Raised by Raymond James $56.52 $38.00 → $102.00
2020-05-12 Buy Target Raised by HC Wainwright $56.52 $60.00 → $69.00

CCXI Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -4.98% during the next 3 months and, with a 90% probability hold a price between $8.45 and $16.28 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-08-03 $8.88 $13.00 $17.12
2021-08-04 $8.87 $12.99 $17.11
2021-08-05 $8.85 $12.97 $17.09
2021-08-06 $8.84 $12.96 $17.08
2021-08-09 $8.82 $12.94 $17.06
2021-08-10 $8.81 $12.93 $17.05
2021-08-11 $8.79 $12.91 $17.04
2021-08-12 $8.78 $12.90 $17.02
2021-08-13 $8.76 $12.89 $17.01
2021-08-16 $8.75 $12.87 $16.99
2021-08-17 $8.74 $12.86 $16.98
2021-08-18 $8.72 $12.84 $16.96
2021-08-19 $8.71 $12.83 $16.95
2021-08-20 $8.69 $12.81 $16.93
2021-08-23 $8.68 $12.80 $16.92
2021-08-24 $8.66 $12.78 $16.91
2021-08-25 $8.65 $12.77 $16.89
2021-08-26 $8.63 $12.76 $16.88
2021-08-27 $8.62 $12.74 $16.86
2021-08-30 $8.61 $12.73 $16.85
2021-08-31 $8.59 $12.71 $16.83
2021-09-01 $8.58 $12.70 $16.82
2021-09-02 $8.56 $12.68 $16.80
2021-09-03 $8.55 $12.67 $16.79
2021-09-07 $8.53 $12.65 $16.78
2021-09-08 $8.52 $12.64 $16.76
2021-09-09 $8.50 $12.63 $16.75
2021-09-10 $8.49 $12.61 $16.73
2021-09-13 $8.48 $12.60 $16.72
2021-09-14 $8.46 $12.58 $16.70

About ChemoCentryx

ChemoCentryx ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States. Its lead drug candidates in clinical development include CCX168, which is in Phase II clinical trials for the treatment of orphan and rare diseases; CCX872, which is in Phase I... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT